Stephen L. Lowe

Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial

Sandeep T. Patil, Lu Zhang, Ferenc Martényi et al. · Nature Medicine · 2007 · 1K citations

Psychiatry, Psychotic Disorder, Medicine +12

Robust Central Reduction of Amyloid-β in Humans with an Orally Available, Non-Peptidic β-Secretase Inhibitor

Patrick C. May, Robert A. Dean, Stephen L. Lowe et al. · Journal of Neuroscience · 2011 · 365 citations · Full text

Robust Central Reduction, Amyloid-β Peptide, Neurochemical Biomarkers +21

Evidence of Glutamatergic Denervation and Possible Abnormal Metabolism in Alzheimer's Disease

Andrew Procter, Alan M. Palmer, Paul T. Francis et al. · Journal of Neurochemistry · 1988 · 197 citations

The Potent BACE1 Inhibitor LY2886721 Elicits Robust Central Aβ Pharmacodynamic Responses in Mice, Dogs, and Humans

Patrick C. May, Brian A. Willis, Stephen L. Lowe et al. · Journal of Neuroscience · 2015 · 195 citations · Full text

Amyloid β, Neurodegenerative Diseases, Amyloid Lowering +15

Topographical distribution of neurochemical changes in Alzheimer's disease

Andrew Procter, Stephen L. Lowe, Alan M. Palmer et al. · Journal of the Neurological Sciences · 1988 · 136 citations

Topographical Distribution, Alzheimer's Disease, Dementia +6